BioXcel Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BioXcel Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q3 2024.
  • BioXcel Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $1.87M, a 53.5% decline year-over-year.
  • BioXcel Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $9.95M, a 49.1% decline year-over-year.
  • BioXcel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $18.6M, a 7.37% increase from 2022.
  • BioXcel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $17.3M, a 10.9% decline from 2021.
  • BioXcel Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $19.5M, a 33.2% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $9.95M $1.87M -$2.15M -53.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $12.1M $1.06M -$5.07M -82.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $17.2M $3.43M -$1.44M -29.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $18.6M $3.6M -$948K -20.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 $19.6M $4.01M -$469K -10.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $20M $6.12M +$1.64M +36.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $18.4M $4.88M +$1.05M +27.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $17.3M $4.55M +$2.31M +103% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 $15M $4.48M -$403K -8.25% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $15.4M $4.48M -$2.29M -33.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $17.7M $3.83M -$1.74M -31.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $19.5M $2.24M -$4.38M -66.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 $23.8M $4.89M -$382K -7.25% Jul 1, 2021 Sep 30, 2021 10-Q 2021-11-10
Q2 2021 $24.2M $6.77M +$4.81M +246% Apr 1, 2021 Jun 30, 2021 10-Q 2021-08-10
Q1 2021 $19.4M $5.57M +$4.79M +617% Jan 1, 2021 Mar 31, 2021 10-Q 2021-05-10
Q4 2020 $14.6M $6.61M +$5.96M +911% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-11
Q3 2020 $8.65M $5.27M +$4.49M +579% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $4.16M $1.96M +$926K +89.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $3.24M $776K +$94K +13.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $3.14M $654K +$522K +395% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 $2.62M $776K -$114K -12.8% Jul 1, 2019 Sep 30, 2019 10-Q 2019-11-14
Q2 2019 $2.73M $1.03M +$289K +39% Apr 1, 2019 Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $2.45M $682K -$637K -48.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 $3.08M $132K -$958K -87.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 $4.04M $890K +$574K +182% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $3.47M $741K +$648K +697% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $2.82M $1.32M +$1.21M +1133% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $1.61M $1.09M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 $316K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $93K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $107K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.